Abstract 5652: Activation of FGF2-FGFR1 pathway in EGFR-mutant lung cancer cell line with long-term gefitinib exposure.
Hideki Terai(Kitasato Institute Hospital), Tomoko Betsuyaku(Tokyo Medical University), Kenzo Soejima(Keio University), Tetsuo Tani(Keio University), Shinnosuke Ikemura(Keio University), Keiko Ohgino(Keio University), Satoshi Yoda(Harvard University), Aoi Kuroda(Keio University), Kota Ishioka(Keio University), Daisuke Arai(Keio University), Junko Hamamoto(Keio University), Katsuhiko Naoki(Broad Institute), Takashi Sato(Kitasato University), Ryosuke Satomi(Tokyo Medical Center), Hiroyuki Yasuda(Keio University), Sohei Nakayama(Beth Israel Deaconess Medical Center)
Cited by 0
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer
|Science Translational Medicine|2013|565
Activating Mutations of the Noonan Syndrome-Associated <b> <i>SHP2/PTPN11</i> </b> Gene in Human Solid Tumors and Adult Acute Myelogenous Leukemia
|Cancer Research|2004|512
<i>In vitro</i> modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant <i>EGFR</i> mutants in non-small-cell lung cancer
|Oncotarget|2015|159
Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in <i>ROS1</i> Fusion–Positive Lung Cancer
|Clinical Cancer Research|2021|137